Definiens broadens Immuno-Oncology service Offer

Washington, D.C., November 08, 2017 – With the start of the

32nd Annual Meeting (November 8th-12th) of the Society for

Immunotherapy of Cancer (SITC) in National Harbor, MD,

Definiens, the leader in Tissue Phenomics® and provider of endto-

end solutions for biomarker programs in immuno-oncology,

unveils its game changing Immuno-Oncology Panel (IO-Panel)

as parts of its groundbreaking new „Insights“-Services

portfolio.

The IO-Panel is a first in class powerful tool in Definiens new portfolio of

modular services. The IO-Panel empowers pharmaceutical immunooncology

(IO) researchers to advance tissue-biomarker-dependent drug

development and to speed up transfer to clinical research. Future

advancements in immuno-oncology depend on broader use of

standardized biomarkers for multiple treatment programs.

„The IO-Panel helps to harmonize and standardize the understanding on

the entire cancer Immune-landscape through an extendable set of seven

core biomarkers in combination with Definiens“ first in class Tissue-

Phonemics®-driven Image analysis services. It helps to remove

uncertainties and to accelerate that patients and healthcare systems

benefit faster from new precision therapies in immuno-oncology.“

comments Ralf Huss, Chief Medical Officer of Definiens.

Thomas Heydler, Chief Executive Officer of Definiens explains further:

„Definiens“ tailored end-to-end solution allows drug researchers to

develop predictive multi-biomarkers based on a defined standard to derisk

trial investments as well as efforts. It will help to accelerate immunooncology

drug development and more effective clinical trials“.

The IO-Panel combines Definiens“ leading digital image analysis

capabilities, powered by Tissue-Phenomics® technology and high-end

consulting services, delivered by a leading team of expert consultants.

Tissue-Phenomics® technology can quantify the relevant spatial relations

of different immuno and tumor cells within the context of the complete

tissue architecture and tumor heterogeneity. By correlating this

information with e.g. patient data, Definiens“ experts generate biological

insights that are needed for true precision medicine.

The IO-Panel is available through Definiens“ new and unique web-based

service platform known as „Insights“. It allows clients to easily access

Definiens“ entire Services portfolio and acts as a central data repository

which supports the collaboration with internal and external stakeholders

in a regulatory compliant environment.

„Definiens“ new modular service portfolio is a milestone for biomarkerdependent

drug development. Harmonizing biomarkers in pre-clinical and

clinical trial programs and adding multi-omics and treatment-data assures

data consistency and learnings across drug projects and indications. „

adds Heinz Oehl, VP Global Marketing and Corporate Business

Development at Definiens.

Definiens once again proves to be a main engine of innovation in immunooncology

and a key partner with expertise to support tissue-based

oncology biomarker programs from start to finish.

Please attend at The Society for Immunotherapy of Cancer’s (SITC) 2017

Pre-Conference „Immuno-Oncology Biomarkers: Today“s Imperatives for

Tomorrow“s Needs“ in National Harbor, MD, our presentation „Multiplex

IHC Immuno-Oncology Panel for Standardized Profiling of the Immune

Status Based on Spatial and Functional Characterization of the Tumor

Microenvironment“ on November 8, 2017 to learn more about the

comprehensive assessment of the immune status provided by Definiens“

IO Panel image and data analysis based on multiplex IHC assays provided

by Mosaic Laboratories, LLC., or visit us at the Definiens congress booth.

About Definiens

Improving patient lives by unlocking the tissue phenome

In oncology, therapeutic strategies have shifted from a direct assault on cancer cells to recruiting the immune

system for that purpose. Our mission is to accelerate breakthroughs in immuno-oncology by helping

pharmaceutical researchers better leverage tissue-based information through Definiens Tissue Phenomics® –

technology. Our expertise accelerates and deepens understanding of disease biology and immune system

mechanisms and allows to bring multi-omics data into a cancer-relevant context, which facilitates the

translation of new insights into novel therapies and treatment strategies. Our vision is to create unique and

actionable patient profiles through harmonized biomarkers for an individualized standard of care, where

patients experience fewer side effects and live longer. Definiens“ proven technology has been used in

thousands of projects, yielding results that have accelerated drug development and produced over 650 peerreviewed

publications.

Definiens is a member of the AstraZeneca group providing products and services to companies across the life

sciences sector, including MedImmune, the global biologics research and development arm of AstraZeneca.

Definiens‘ Tissue Phenomics approach was awarded the 2013 Frost and Sullivan Company of the Year Award

for Global Tissue Diagnostics and Pathology Imaging. For more information, please visit: www.definiens.com

Safe Harbor Statement

This press release contains „forward-looking statements“ within the meaning of the Private Securities Litigation

Reform Act of 1995, including statements relating to data being presented at the at the 2017 Society for

Immunotherapy of Cancer (SITC) held November 10-11, 2017 in National Harbor, MD. These „forward-looking

statements“ are based on management’s current expectations of future events and are subject to a number of

risks and uncertainties that could cause actual results to differ materially and adversely from those described

or implied in the forward-looking statements.

Kontakt
Definiens AG
Heinz Oehl
Bernhard-Wicki-Straße 5
80636 München
+49 (0) 89 231180-00
press@definiens.com
http://www.definiens.com